acetaminophen; ibuprofen sodium · Hikma · NDA 215320

Combogesic Iv

Earliest generic entry, as listed
14 Jan 2036

Blocked by patent: US 11213498.

Listed patents · 6 unexpired

10 Orange Book listing rows for 6 patents. FDA lists a patent once for each use code, and lists its pediatric extension as a separate row.

PatentClaimsExpires
US 11213498drug product · sets the listed date14 Jan 2036
US 11389416drug product17 Jul 2035
US 12083087use U-3744, U-374517 Jul 2035
US 12083087 listing rowuse U-374417 Jul 2035
US 12083087 listing rowuse U-374517 Jul 2035
US 11446266use U-3744, U-374526 Oct 2031
US 11446266 listing rowuse U-374426 Oct 2031
US 11446266 listing rowuse U-374526 Oct 2031
US 11896567use U-3744, U-374526 Oct 2031
US 11896567 listing rowuse U-374426 Oct 2031
US 11896567 listing rowuse U-374526 Oct 2031
US 12220392use U-4306, U-430726 Oct 2031
US 12220392 listing rowuse U-430626 Oct 2031
US 12220392 listing rowuse U-430726 Oct 2031

Exclusivities · 0 unexpired

No unexpired exclusivities listed.

Paragraph IV certifications · 0

No Paragraph IV certification listed by FDA for this drug.

The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.

Event history

No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.

Products covered · 1

NDA · productFormStrengthListed expiry
215320 · 001 · RLDsolution, intravenous1GM/100ML (10MG/ML);EQ 300MG BASE/100ML (EQ 3MG BASE/ML)14 Jan 2036
Expired or delisted (1)
  • NP · 17 Oct 2026